Literature DB >> 28257593

Characterization of structural and immunological properties of a fusion protein between flagellin from Salmonella and lumazine synthase from Brucella.

Y Hiriart1, A H Rossi2, M E Biedma1, A J Errea1, G Moreno1, D Cayet3, J Rinaldi2, B Blancá1, J C Sirard3, F Goldbaum2, P Berguer2, M Rumbo1.   

Abstract

Aiming to combine the flexibility of Brucella lumazine synthase (BLS) to adapt different protein domains in a decameric structure and the capacity of BLS and flagellin to enhance the immunogenicity of peptides that are linked to their structure, we generated a chimeric protein (BLS-FliC131) by fusing flagellin from Salmonella in the N-termini of BLS. The obtained protein was recognized by anti-flagellin and anti-BLS antibodies, keeping the oligomerization capacity of BLS, without affecting the folding of the monomeric protein components determined by circular dichroism. Furthermore, the thermal stability of each fusion partner is conserved, indicating that the interactions that participate in its folding are not affected by the genetic fusion. Besides, either in vitro or in vivo using TLR5-deficient animals we could determine that BLS-FliC131 retains the capacity of triggering TLR5. The humoral response against BLS elicited by BLS-FliC131 was stronger than the one elicited by equimolar amounts of BLS + FliC. Since BLS scaffold allows the generation of hetero-decameric structures, we expect that flagellin oligomerization on this protein scaffold will generate a new vaccine platform with enhanced capacity to activate immune responses.
© 2017 The Protein Society.

Entities:  

Keywords:  BLS; TLR5; flagellin; scaffold

Mesh:

Substances:

Year:  2017        PMID: 28257593      PMCID: PMC5405423          DOI: 10.1002/pro.3151

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  44 in total

1.  Deletion of flagellin's hypervariable region abrogates antibody-mediated neutralization and systemic activation of TLR5-dependent immunity.

Authors:  Clément Nempont; Delphine Cayet; Martin Rumbo; Coralie Bompard; Vincent Villeret; Jean-Claude Sirard
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

2.  Down-regulation of intestinal epithelial innate response by probiotic yeasts isolated from kefir.

Authors:  David Romanin; María Serradell; Dolores González Maciel; Natalia Lausada; Graciela L Garrote; Martín Rumbo
Journal:  Int J Food Microbiol       Date:  2010-04-21       Impact factor: 5.277

3.  CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis.

Authors:  Silvia Affò; Oriol Morales-Ibanez; Daniel Rodrigo-Torres; José Altamirano; Delia Blaya; Dianne H Dapito; Cristina Millán; Mar Coll; Jorge M Caviglia; Vicente Arroyo; Juan Caballería; Robert F Schwabe; Pere Ginès; Ramón Bataller; Pau Sancho-Bru
Journal:  Gut       Date:  2014-01-10       Impact factor: 23.059

4.  Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease.

Authors:  Chandrabali Ghose; Janneke M Verhagen; Xinhua Chen; Jian Yu; Yaoxing Huang; Olivia Chenesseau; Ciarán P Kelly; David D Ho
Journal:  Infect Immun       Date:  2013-04-01       Impact factor: 3.441

5.  Determination of the physiological 2:2 TLR5:flagellin activation stoichiometry revealed by the activity of a fusion receptor.

Authors:  Karolina Ivičak-Kocjan; Gabriela Panter; Mojca Benčina; Roman Jerala
Journal:  Biochem Biophys Res Commun       Date:  2013-04-25       Impact factor: 3.575

6.  Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity.

Authors:  James W Huleatt; Andrea R Jacobs; Jie Tang; Priyanka Desai; Elizabeth B Kopp; Yan Huang; Langzhou Song; Valerian Nakaar; T J Powell
Journal:  Vaccine       Date:  2006-08-22       Impact factor: 3.641

7.  A fusion protein of flagellin and ovalbumin suppresses the TH2 response and prevents murine intestinal allergy.

Authors:  Stefan Schülke; Manja Burggraf; Zoe Waibler; Andrea Wangorsch; Sonja Wolfheimer; Ulrich Kalinke; Stefan Vieths; Masako Toda; Stephan Scheurer
Journal:  J Allergy Clin Immunol       Date:  2011-08-26       Impact factor: 10.793

Review 8.  Mucosal interplay among commensal and pathogenic bacteria: lessons from flagellin and Toll-like receptor 5.

Authors:  Martin Rumbo; Clément Nempont; Jean-Pierre Kraehenbuhl; Jean-Claude Sirard
Journal:  FEBS Lett       Date:  2006-04-21       Impact factor: 4.124

9.  Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used.

Authors:  Carlos A Velikovsky; Fernando A Goldbaum; Juliana Cassataro; Silvia Estein; Raúl A Bowden; Laura Bruno; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

10.  Generation and selection of anti-flagellin monoclonal antibodies useful for serotyping Salmonella enterica.

Authors:  Yanina Hiriart; Maria Serradell; Araci Martínez; Sofia Sampaolesi; Dolores Gonzalez Maciel; Jose Alejandro Chabalgoity; Lucía Yim; Gabriela Algorta; Martin Rumbo
Journal:  Springerplus       Date:  2013-11-28
View more
  3 in total

Review 1.  Bioengineering Strategies for Protein-Based Nanoparticles.

Authors:  Dennis Diaz; Andrew Care; Anwar Sunna
Journal:  Genes (Basel)       Date:  2018-07-23       Impact factor: 4.096

2.  Covalent coupling of Spike's receptor binding domain to a multimeric carrier produces a high immune response against SARS-CoV-2.

Authors: 
Journal:  Sci Rep       Date:  2022-01-13       Impact factor: 4.379

Review 3.  Bacterial flagellin-a potent immunomodulatory agent.

Authors:  Irshad A Hajam; Pervaiz A Dar; Imam Shahnawaz; Juan Carlos Jaume; John Hwa Lee
Journal:  Exp Mol Med       Date:  2017-09-01       Impact factor: 8.718

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.